HealthEquity Valuation
| HQY Stock | USD 73.21 3.71 4.82% |
At this time, the firm appears to be overvalued. HealthEquity retains a regular Real Value of $68.09 per share. The prevalent price of the firm is $73.21. Our model calculates the value of HealthEquity from evaluating the firm fundamentals such as return on equity of 0.0901, and Return On Asset of 0.0544 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting HealthEquity's valuation include:
Price Book 3.0791 | Enterprise Value | Enterprise Value Ebitda 15.8211 | Price Sales 5.1537 | Forward PE 17.1821 |
Overvalued
Today
Please note that HealthEquity's price fluctuation is very steady at this time. Calculation of the real value of HealthEquity is based on 3 months time horizon. Increasing HealthEquity's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since HealthEquity is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HealthEquity Stock. However, HealthEquity's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 73.21 | Real 68.09 | Target 119.13 | Hype 73.21 |
The intrinsic value of HealthEquity's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence HealthEquity's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of HealthEquity helps investors to forecast how HealthEquity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HealthEquity more accurately as focusing exclusively on HealthEquity's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use HealthEquity's intrinsic value based on its ongoing forecasts of HealthEquity's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against HealthEquity's closest peers.
HealthEquity Cash |
|
HealthEquity Revenue by Product
HealthEquity Total Value Analysis
HealthEquity is currently projected to have company total value of 7.29 B with market capitalization of 6.65 B, debt of 1.11 B, and cash on hands of 176.89 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the HealthEquity fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.29 B | 6.65 B | 1.11 B | 176.89 M |
HealthEquity Investor Information
About 98.0% of the company shares are owned by institutional investors. The book value of HealthEquity was currently reported as 24.93. The company has Price/Earnings To Growth (PEG) ratio of 0.69. HealthEquity had not issued any dividends in recent years. Based on the key measurements obtained from HealthEquity's financial statements, HealthEquity may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.19 | 0.22 |
|
| |||||
| Total Cash From Operating Activities | 410.4 M | 390.8 M |
|
| |||||
| Operating Income | 277.8 M | 264.6 M |
|
|
HealthEquity Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. HealthEquity has an asset utilization ratio of 34.79 percent. This suggests that the Company is making $0.35 for each dollar of assets. An increasing asset utilization means that HealthEquity is more efficient with each dollar of assets it utilizes for everyday operations.HealthEquity Profitability Analysis
Based on the key profitability measurements obtained from HealthEquity's financial statements, HealthEquity's profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess HealthEquity's ability to earn profits and add value for shareholders.Net Income | First Reported 2012-04-30 | Previous Quarter 59.9 M | Current Value 51.7 M | Quarterly Volatility 16.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.58 | 0.66 |
|
| |||||
| Operating Profit Margin | 0.19 | 0.22 |
|
|
For HealthEquity profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HealthEquity to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HealthEquity utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HealthEquity's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HealthEquity over time as well as its relative position and ranking within its peers.
HealthEquity Earnings per Share Projection vs Actual
The next projected EPS of HealthEquity is estimated to be 1.141525 with future projections ranging from a low of 1.085 to a high of 1.26125. HealthEquity's most recent 12-month trailing earnings per share (EPS TTM) is at 2.18. Please be aware that the consensus of earnings estimates for HealthEquity is based on EPS before non-recurring items and includes expenses related to employee stock options.HealthEquity Earnings Estimation Breakdown
The calculation of HealthEquity's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of HealthEquity is estimated to be 1.141525 with the future projection ranging from a low of 1.085 to a high of 1.26125. Please be aware that this consensus of annual earnings estimates for HealthEquity is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.08 Lowest | Expected EPS | 1.26 Highest |
HealthEquity Earnings Projection Consensus
Suppose the current estimates of HealthEquity's value are higher than the current market price of the HealthEquity stock. In this case, investors may conclude that HealthEquity is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and HealthEquity's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of January 2027 | Current EPS (TTM) | |
| 16 | 84.61% | 0.0 | 1.141525 | 2.18 |
HealthEquity Ownership Allocation
The majority of HealthEquity outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in HealthEquity to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in HealthEquity. Please pay attention to any change in the institutional holdings of HealthEquity as this could imply that something significant has changed or is about to change at the company.HealthEquity Profitability Analysis
The company reported the last year's revenue of 1.2 B. Total Income to common stockholders was 96.7 M with profit before taxes, overhead, and interest of 874.01 M.About HealthEquity Valuation
Our relative valuation model uses a comparative analysis of HealthEquity. We calculate exposure to HealthEquity's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of HealthEquity's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 796.5 M | 836.3 M | |
| Pretax Profit Margin | 0.11 | 0.12 | |
| Operating Profit Margin | 0.22 | 0.19 | |
| Net Profit Margin | 0.09 | 0.11 | |
| Gross Profit Margin | 0.66 | 0.58 |
HealthEquity Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 88.8 M | |
| Quarterly Earnings Growth Y O Y | 8.833 | |
| Forward Price Earnings | 17.1821 |
HealthEquity Current Valuation Indicators
Valuation refers to the process of determining the present value of HealthEquity and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value HealthEquity we look at many different elements of the entity such as HealthEquity's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as HealthEquity, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use HealthEquity's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes HealthEquity's worth.Additional Tools for HealthEquity Stock Analysis
When running HealthEquity's price analysis, check to measure HealthEquity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HealthEquity is operating at the current time. Most of HealthEquity's value examination focuses on studying past and present price action to predict the probability of HealthEquity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HealthEquity's price. Additionally, you may evaluate how the addition of HealthEquity to your portfolios can decrease your overall portfolio volatility.